Abstract: Objective To investigate the paclitaxel lipid body and traditional paclitaxel combined with carboplatin in the treatment of ovarian cancer the curative effect and adverse reaction of contrast analysis. Methods Altogether 92 patients with late-stage ovarian cancer were divided into two groups,with 46 cases in each group.Study group was treated with paclitaxel liposome combined with carboplatin chemotherapy.The control group used traditional paclitaxel and carboplatin chemotherapy.The clinical effect and adverse reaction of the two groups after treatment were compared. Results The total effectiveness rate was 76.09% in the study group and 69.57% in the control group.There was no significant difference between the two groups (P>0.05).The white blood cell reduction,thrombocytopenia,hemoglobin reduction,renal dysfunction,diarrhea,hair loss,and incidence of anorexia between the two groups were compared.The difference was not statistically significant (P>0.05).Muscle and joint pain (4.35%),dyspnea (2.17%),nausea (13.04%),vomiting (13.04%),facial flushing (8.70%),peripheral neurotoxicity (4.35%),rash of incidence of the study group were significantly lower than those of the control group (21.74%,15.22%,34.78%,36.96%,28.26%,19.57%).The difference was statistically significant (χ²=6.133,4.929,5.974,7.015,5.845,5.060,P<0.05). Conclusion The curative effects of paclitaxel lipid body and traditional paclitaxel plus carboplatin in the treatment of ovarian cancer were even,but the adverse reactions of paclitaxel liposome occurred was significantly lower than that of the conventional paclitaxel.